Study Reveals Radiation Therapy's Role in Promoting Metastatic Growth

Recent research published in Nature has uncovered significant insights into the effects of radiation therapy on metastatic tumor growth, particularly concerning the epidermal growth factor receptor (EGFR) ligand known as amphiregulin. The study highlights how radiation therapy can inadvertently stimulate this ligand, leading to an increase in the size and prevalence of metastases in patients with advanced solid tumors.

The research team from the University of Chicago, led by Dr. András Piffkó, investigated the impact of stereotactic body radiotherapy on patients undergoing treatment for multiple metastatic sites. They analyzed gene expression changes by examining matched tissue samples from 22 patients before and after receiving radiation treatment.

The findings revealed that radiation therapy significantly induced the expression of amphiregulin within tumor cells. This ligand was found to reprogram EGFR-expressing myeloid cells to adopt an immunosuppressive state, effectively diminishing their ability to clear cancer cells through phagocytosis. Notably, amphiregulin was linked to several of the most significantly upregulated gene pathways associated with tumor progression.

Patients exhibiting heightened levels of amphiregulin in their tumors demonstrated a marked decrease in both progression-free and overall survival rates. While local radiotherapy effectively reduced the number of lung metastases, it paradoxically contributed to an increase in their size due to amphiregulin secretion. This response was mitigated when gene knockout techniques were employed. The researchers further validated their results using mouse models of lung metastasis, which also indicated that blocking amphiregulin could counteract its detrimental effects.

Dr. Ralph R. Weichselbaum, a senior author of the study, noted that combining radiation therapy with amphiregulin blockade led to reductions in both tumor size and the quantity of metastatic sites. These findings underscore the complex interplay between therapeutic interventions and tumor biology, emphasizing the importance of understanding the mechanisms by which treatments can influence cancer progression.

As the research community continues to explore the ramifications of these findings, the implications for clinical practice could be significant, prompting a reevaluation of radiation therapy protocols in patients with metastatic disease. The study's authors also disclosed affiliations with the biopharmaceutical industry, suggesting potential avenues for future therapeutic strategies aimed at mitigating the risks associated with radiation-induced metastasis.